Investing.com -- Cardiff Oncology Inc (NASDAQ: CRDF) reported second-quarter earnings that missed analyst expectations, sending shares tumbling 22% as investors reacted to the wider-than-expected loss ...

The company ended the quarter with $510 million in debt and net debt of $479 million, up from $498 million and $464 million respectively at the end of the first quarter. Ryerson’s board declared a ...

BlueLinx’s performance was hampered by challenging market conditions despite volume increases in both specialty and structural products. Gross profit declined 2% YoY to $120 million, with gross margin ...

The footwear manufacturer posted adjusted earnings of $0.55 per diluted share for the quarter ended June 30, 2025, more than double the analyst estimate of $0.25. Revenue climbed 7.5% YoY to $105.6 ...

Investing.com -- Aclaris Therapeutics Inc (NASDAQ: ACRS) stock surged 20% in after-hours trading following the announcement of positive top-line results from its Phase 2a trial of ATI-2138 in patients ...